

Recombinant Human BCMA/TNFRSF17

Cat.No.:MGC135 size:5µg/50µg/500µg

Characteristics:

Source	<i>E.coli</i>
Species	Human
Tag	Tag free
Description	Human BCMA/TNFRSF17 (Ala5-Ala54)
Accession#	Q02223
Predicted molecular mass	~5.4 kDa. It is composed of one non-glycosylated polypeptide chain containing 50 amino acids.

Specification:


Appearance	White powder, Colorless clear liquid after reconstitution
Purity	≥95%,by SDS-PAGE(under reducing(R)&Non-reducing conditions, visualized by Coomassie staining)
Endotoxin	< 0.1 EU/µg
Activity	The ED50 as determined by its ability to inhibit APRIL-mediated proliferation of anti-IgM stimulated murine B cells is no less than 40 ng/ml, corresponding to a specific activity of $\geq 2.5 \times 10^4$ IU/mg in the presence of 100 ng/ml human APRIL.
Formulation	0.2 µm-filtered solution containing 30% acetonitrile, 0.1% TFA.

Handling and Storage:

Reconstitution	It is recommended to redissolve in sterile deionized water. 细胞因子溶解、稀释、保存可使用即用型专用溶剂套装—PWL240（1mL无菌水+10mL稀释液）
Shipping	Wet ice (seasonal)
Storage & Stability	36 months at -20°C to -80°C in lyophilized state 6 months at -20°C to -80°C under sterile conditions after reconstitution 7-10 days at 2°C to 8°C under sterile conditions after reconstitution Use a manual defrost freezer and avoid repeated freeze-thaw cycles.


Data:

SDS-PAGE



Recombinant Human BCMA/TNFRSF17 (Cat. No. MGC135) SDS-PAGE under reducing (R) & Non-reducing conditions.

Bioactivity



The ED50 as determined by its ability to inhibit APRIL-mediated proliferation of anti-IgM stimulated murine B cells is no less than 40 ng/ml, corresponding to a specific activity of $\geq 2.5 \times 10^4$ IU/mg in the presence of 100 ng/ml human APRIL.

S260701